CLL-Current and Emerging Therapies

Article

Please join us for our upcoming telephone/web education program, CLL- Current and Emerging Therapies on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.

Thomas Kipps, MD

Please join us for our upcoming telephone/web education program,

CLL- Current and Emerging Therapies

on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.

Topics will include:

  • The goal of CLL treatment
  • How staging influences personalized treatment planning
  • Current treatment options for CLL
  • Emerging therapies and clinical trials for CLL
  • Side effects management
  • The importance of open communication with your treatment team

For more information, please contact the Leukemia & Lymphoma’s Information Resource Center at 800-955-4572 or

www.LLS.org/programs

.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Elizabeth Aronson
Shivani Gopalsami
Donna Catamero
Related Content
Line illustration of red blood cells on a yellow background

Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

Russ Conroy
April 20th 2025
Article

Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Aerial photo of four medical professionals talking in a huddle; two are wearing scrubs and two are wearing lab coats

Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden

Bridget Hoyt
Published: March 19th 2025 | Updated: March 19th 2025
Article

Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Simple white line illustration of a clipboard that says "FDA" at the top, with a checkmark symbol overlapping the clipboard

Oncology Drugs Approved by the FDA in January 2025

Darlene Dobkowski, MA
February 3rd 2025
Article

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Simple white line illustration of red blood cells on a yellow background

Evaluating the Risk of Second Primary Cancers After CAR T-Cell Therapy

Ashling Wahner
January 30th 2025
Article

The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.